<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002201</url>
  </required_header>
  <id_info>
    <org_study_id>245D</org_study_id>
    <secondary_id>M96-581</secondary_id>
    <nct_id>NCT00002201</nct_id>
  </id_info>
  <brief_title>A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients</brief_title>
  <official_title>Safety and Efficacy of Ritonavir (ABT-538) in Combination With Nelfinavir in HIV-Infected Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give ritonavir plus
      nelfinavir to HIV-infected patients. This study will also see how ritonavir and nelfinavir
      are absorbed by the body and how they affect the level of HIV in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  Documentation of a positive ELISA test for HIV confirmed by immunoblot, or a positive
             HIV RNA test using the Roche PCR assay, or the Chiron bDNA assay.

          -  HIV RNA measurement of &gt; 5,000 copies/ml within 3 weeks of baseline visit.

          -  Signed, informed consent from parent or legal guardian for patients less than 18 years
             of age.

          -  Access to a refrigerator for storing study drug.

        Prior Medication:

        Allowed:

        Anti-HIV therapy other than protease inhibitor therapy.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Evidence of acute infection, as measured by vital signs, physical examination, 12-lead
             electrocardiogram and laboratory assessments.

          -  Condition that may obscure the proper observation of the safety or activity of the
             treatment regimens.

        Concurrent Medication:

        Excluded:

          -  Midazolam, alprazolam, clorazepate, diazepam, estazolam, flurazepam, triazolam,
             zolpidem, quinidine, amiodarone, encainide, flecainide, propafenone, bepridil,
             terfenadine, astemizole, cisapride, bupropion, clozapine, rifabutin, meperidine,
             propoxyphene, piroxicam, pimozide, ergotamine, dihydroergotamine, and rifampin.

          -  Anti-retroviral therapy initiated prior to study entry.

          -  Any other medication, including over-the-counter medicine and alcohol, taken without
             the permission of the primary investigator.

        Patients with the following prior conditions are excluded:

          -  History of significant drug hypersensitivity.

          -  History of psychiatric illness that would preclude compliance with the protocol.

          -  Prior enrollment in this study.

        Prior Medication:

        Excluded:

          -  Investigational drugs within 30 days prior to drug administration.

          -  Prior treatment with licensed or investigational HIV protease inhibitor.

             1. Active substance abuse.

          -  Positive urine screen for recreational drugs. NOTE:

          -  The presence of cannabis is not exclusionary unless the investigator believes its use
             will interfere with patient compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Raines CP, Flexner C, Sun E, Heath-Chiozzi M, Lewis RH, Fields C, Deetz C, Apuzzo L, Eshleman SH, Jackson JB, Gallant JE. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. J Acquir Immune Defic Syndr. 2000 Dec 1;25(4):322-8.</citation>
    <PMID>11114832</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>February 19, 2009</last_update_submitted>
  <last_update_submitted_qc>February 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2009</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Nelfinavir</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

